Bellerophon Therapeutics, Inc. – NASDAQ:BLPH
Bellerophon Therapeutics stock price monthly change
Bellerophon Therapeutics stock price quarterly change
Bellerophon Therapeutics stock price yearly change
Bellerophon Therapeutics key metrics
Market Cap | 146.79K |
Enterprise value | N/A |
P/E | -0.02 |
EV/Sales | N/A |
EV/EBITDA | 0.57 |
Price/Sales | N/A |
Price/Book | 0.03 |
PEG ratio | N/A |
EPS | -1.08 |
Revenue | N/A |
EBITDA | -11.17M |
Income | -11.67M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBellerophon Therapeutics stock price history
Bellerophon Therapeutics stock forecast
Bellerophon Therapeutics financial statements
| Dec 2022 | 0 | -7.43M | |
|---|---|---|---|
| Mar 2023 | 5.64M | 2.82M | 50.04% |
| Jun 2023 | 0 | -5.13M | |
| Sep 2023 | 0 | -1.92M |
| 2025 | 7.62M | -7.44M | -97.76% |
|---|
Analysts Price target
Financials & Ratios estimates
| Dec 2022 | 7935000 | 5.40M | 68.07% |
|---|---|---|---|
| Mar 2023 | 15966000 | 5.36M | 33.6% |
| Jun 2023 | 11245000 | 5.62M | 50% |
| Sep 2023 | 4979000 | 1.25M | 25.23% |
| Dec 2022 | -4.35M | 0 | 0 |
|---|---|---|---|
| Mar 2023 | 3.26M | 0 | 4.98M |
| Jun 2023 | -4.92M | 0 | 26K |
| Sep 2023 | -6.33M | 0 | 0 |
Bellerophon Therapeutics alternative data
| Aug 2023 | 18 |
|---|---|
| Sep 2023 | 18 |
| Oct 2023 | 18 |
| Nov 2023 | 18 |
| Dec 2023 | 18 |
| Jan 2024 | 18 |
| Feb 2024 | 18 |
| Mar 2024 | 18 |
| Apr 2024 | 18 |
| May 2024 | 18 |
| Jun 2024 | 18 |
| Jul 2024 | 18 |
Bellerophon Therapeutics other data
| Period | Buy | Sel |
|---|---|---|
| May 2023 | 0 | 569455 |
| Jun 2023 | 0 | 134421 |
| Oct 2023 | 0 | 1076841 |
| Quarter | Transcript |
|---|---|
| Q4 2015 21 Mar 2016 | Q4 2015 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Peter Fernandes M. Pharm (1955) Interim Principal Executive Officer, Chief Regulatory & Safety Officer | $476,350 |
-
When is Bellerophon Therapeutics's next earnings date?
Unfortunately, Bellerophon Therapeutics's (BLPH) next earnings date is currently unknown.
-
Does Bellerophon Therapeutics pay dividends?
Yes, Bellerophon Therapeutics pays dividends and its trailing 12-month yield is 158.04% with 0% payout ratio. The last Bellerophon Therapeutics stock dividend of undefined was paid on 6 Sep 2025.
-
How much money does Bellerophon Therapeutics make?
Bellerophon Therapeutics has a market capitalization of 146.79K.
-
What is Bellerophon Therapeutics's stock symbol?
Bellerophon Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "BLPH".
-
What is Bellerophon Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Bellerophon Therapeutics?
Shares of Bellerophon Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Bellerophon Therapeutics's key executives?
Bellerophon Therapeutics's management team includes the following people:
- Mr. Peter Fernandes M. Pharm Interim Principal Executive Officer, Chief Regulatory & Safety Officer(age: 70, pay: $476,350)
-
How many employees does Bellerophon Therapeutics have?
As Jul 2024, Bellerophon Therapeutics employs 18 workers.
-
When Bellerophon Therapeutics went public?
Bellerophon Therapeutics, Inc. is publicly traded company for more then 10 years since IPO on 13 Feb 2015.
-
What is Bellerophon Therapeutics's official website?
The official website for Bellerophon Therapeutics is bellerophon.com.
-
Where are Bellerophon Therapeutics's headquarters?
Bellerophon Therapeutics is headquartered at 184 Liberty Corner Road, Warren, NJ.
-
How can i contact Bellerophon Therapeutics?
Bellerophon Therapeutics's mailing address is 184 Liberty Corner Road, Warren, NJ and company can be reached via phone at +90 85744770.
Bellerophon Therapeutics company profile:
Bellerophon Therapeutics, Inc.
bellerophon.comNASDAQ
18
Biotechnology
Healthcare
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Warren, NJ 07059
CIK: 0001600132
ISIN: US0787713009
CUSIP: 078771300
